The Effects of Flaxseed Supplement on Weight and Biochemical Factors in Overweight and Obese Subject
The Effects of Flaxseed Supplement on Weight, Lipid Profile and Inflammatory Factors in Overweight and Obese Subjects
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 3
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age of 18 to 70 years
- Body Mass Index (BMI) between 25-40
Exclusion Criteria:
- diabetes mellitus
- cardiovascular diseases and cancers
- major systemic diseases
- gastrointestinal problems
- liver and renal failure
- history of allergy or high consumption of nuts, flaxseed, or sesame seeds
- weight loss within the past 6 mo of >5% of body weight or current adherence to a weight-reduction diet
- pregnancy, lactation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: control
dietary and exercise recommendation
|
|
|
Active Comparator: Flaxseed
30 grams Flaxseed powder combine with dietary and exercise recommendation
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
weight
Time Frame: 12 weeks
|
12 weeks
|
|
waist and hip circumference
Time Frame: 12 weeks
|
12 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
lipid profile
Time Frame: 12 weeks
|
12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 1368
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Overweight and Obesity
-
NCT03843424CompletedOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood
-
NCT04297722CompletedObesity, Childhood | Overweight and Obesity | Overweight, Childhood
-
NCT07395466Active, not recruitingObesity | Overweight and/or Obesity | Overweight or Obese Adults | Overweight , Obesity
-
NCT05038683RecruitingChildhood Overweight and Obesity
-
NCT07342855RecruitingPediatric Obesity | Pediatric Overweight | Overweight , Obesity
-
NCT07575932Not yet recruitingObesity | Overnutrition | Nutrition Disorders | Overweight | Body Weight | Overweight or Obesity | Overweight and/or Obesity | Nutritional and Metabolic Diseases
-
NCT05676229RecruitingObesity | Overweight and Obesity | Obesity; Endocrine | Overweight, Obesity and Other Hyperalimentation
-
NCT04250896CompletedOverweight and Obesity
-
NCT03881280Completed
Clinical Trials on Placebo
-
NCT03827590UnknownAcute Bronchitis | Acute Upper Respiratory Tract Infection
-
NCT02177513Completed
-
NCT02935712CompletedMale Subjects With Type II Diabetes (T2DM)
-
NCT06767540Not yet recruiting
-
NCT03198624CompletedPharmacokinetics | Safety Issues
-
NCT02982187CompletedPulmonary Disease, Chronic Obstructive
-
NCT04693039Completed
-
NCT01610388Completed
-
NCT04388215UnknownHypertension | Dyslipidemias